GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy
Similar Posts
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2024 to 2025
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
MHRA statement on Pathways clinical trial
As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants.
Guidance: AI Airlock Background
Background information for MHRA AI Airlock launched in Spring 2024 and is the MHRA’s first regulatory sandbox for AI as a Medical Device (AIaMD) products.
UK medical device testing hits record high as MHRA backs growth in brain and AI technology
Patients benefit from earlier access to technologies that could improve or save lives, as the MHRA approved 17 per cent more clinical investigations in 2025 compared with 2024, and launches measures to support innovation and growth.
Form: Medicines: variation forms for a manufacturer’s licence
Forms to make a variation to a manufacturer’s licence.
From Brussels sprouts to mobility scooters: five tips from the MHRA for staying safe and well over the festive period
The MHRA has five top tips to help you stay well through the festive season and beyond